Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes.

Anatomic site Merkel cell carcinoma Radiation therapy Surgery

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 14 04 2023
revised: 19 07 2023
accepted: 24 08 2023
pubmed: 3 9 2023
medline: 3 9 2023
entrez: 2 9 2023
Statut: ppublish

Résumé

Clinically localized Merkel cell carcinoma (MCC) has been associated with high rates of disease relapse. This study examines how primary tumor anatomic site drives patterns of care and outcomes in a large cohort treated in the contemporary era. Patterns of care and associated outcomes were evaluated for clinically Stage I-II MCC patients treated at our institution with adjuvant radiation therapy (RT) to the primary site and/or regional nodal basin as a component of their curative intent therapy between 2014-2021. Of 80 patients who met inclusion criteria, the primary tumor anatomic site was head and neck (HN) for 42 (53%) and non-head and neck (NHN) for 38 (47%). Primary tumor risk factors were similar between cohorts. Fewer patients with HN tumors had wide local excision (WLE; HN-81% vs. NHN-100% p < 0.01). Of those undergoing WLE, patients with HN tumors received higher dose adjuvant RT (>50 Gy: HN-70% vs. NHN-8%; p < 0.01). Patients with HN tumors were less likely to undergo sentinel lymph node biopsy (HN-62%vs. NHN-100%; p < 0.01) and more likely to have elective nodal RT (HN-48% vs. NHN-0%). Despite varying management strategies, there was no significant difference in local recurrence-free survival (3-yr LRFS HN-94% vs. NHN-94%; p = 0.97), nodal recurrence-free survival (3-yr NRFS HN-89% vs. NHN-85%; p = 0.71) or overall recurrence-free survival (3-yr RFS 73% HN vs. 80% NHN; p = 0.44). Among patients with primary MCC who had RT as a component of their initial treatment strategy, anatomically-driven heterogeneous treatment approaches were associated with equally excellent locoregional disease control.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
Clinically localized Merkel cell carcinoma (MCC) has been associated with high rates of disease relapse. This study examines how primary tumor anatomic site drives patterns of care and outcomes in a large cohort treated in the contemporary era.
MATERIALS AND METHODS METHODS
Patterns of care and associated outcomes were evaluated for clinically Stage I-II MCC patients treated at our institution with adjuvant radiation therapy (RT) to the primary site and/or regional nodal basin as a component of their curative intent therapy between 2014-2021.
RESULTS RESULTS
Of 80 patients who met inclusion criteria, the primary tumor anatomic site was head and neck (HN) for 42 (53%) and non-head and neck (NHN) for 38 (47%). Primary tumor risk factors were similar between cohorts. Fewer patients with HN tumors had wide local excision (WLE; HN-81% vs. NHN-100% p < 0.01). Of those undergoing WLE, patients with HN tumors received higher dose adjuvant RT (>50 Gy: HN-70% vs. NHN-8%; p < 0.01). Patients with HN tumors were less likely to undergo sentinel lymph node biopsy (HN-62%vs. NHN-100%; p < 0.01) and more likely to have elective nodal RT (HN-48% vs. NHN-0%). Despite varying management strategies, there was no significant difference in local recurrence-free survival (3-yr LRFS HN-94% vs. NHN-94%; p = 0.97), nodal recurrence-free survival (3-yr NRFS HN-89% vs. NHN-85%; p = 0.71) or overall recurrence-free survival (3-yr RFS 73% HN vs. 80% NHN; p = 0.44).
CONCLUSIONS CONCLUSIONS
Among patients with primary MCC who had RT as a component of their initial treatment strategy, anatomically-driven heterogeneous treatment approaches were associated with equally excellent locoregional disease control.

Identifiants

pubmed: 37659660
pii: S0167-8140(23)89786-9
doi: 10.1016/j.radonc.2023.109892
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109892

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Samuel Cass (S)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Brandon Cope (B)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Andrew J Bishop (AJ)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Yi-Ju Chiang (YJ)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

B Ashleigh Guadagnolo (B)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Ahsan Farooqi (A)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

William Morrison (W)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Russell G Witt (RG)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Riyad N H Seervai (RNH)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas, United States.

Adam S Garden (AS)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Clifton D Fuller (CD)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Ryan P Goepfert (RP)

Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Merrick Ross (M)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Jeffrey E Gershenwald (JE)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Michael Wong (M)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Phyu P Aung (PP)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Emily Z Keung (EZ)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Devarati Mitra (D)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States. Electronic address: dmitra@mdanderson.org.

Classifications MeSH